[go: up one dir, main page]

GB9105245D0 - Binding molecules - Google Patents

Binding molecules

Info

Publication number
GB9105245D0
GB9105245D0 GB919105245A GB9105245A GB9105245D0 GB 9105245 D0 GB9105245 D0 GB 9105245D0 GB 919105245 A GB919105245 A GB 919105245A GB 9105245 A GB9105245 A GB 9105245A GB 9105245 D0 GB9105245 D0 GB 9105245D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919105245A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynxvale Ltd
Original Assignee
Lynxvale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynxvale Ltd filed Critical Lynxvale Ltd
Priority to GB919105245A priority Critical patent/GB9105245D0/en
Publication of GB9105245D0 publication Critical patent/GB9105245D0/en
Priority to JP4505594A priority patent/JPH06510659A/en
Priority to PCT/GB1992/000445 priority patent/WO1992016562A1/en
Priority to EP19920906335 priority patent/EP0575407A1/en
Priority to CA 2105980 priority patent/CA2105980A1/en
Pending legal-status Critical Current

Links

GB919105245A 1991-03-12 1991-03-12 Binding molecules Pending GB9105245D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB919105245A GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules
JP4505594A JPH06510659A (en) 1991-03-12 1992-03-12 Humanized antibodies with altered allotypic determinants
PCT/GB1992/000445 WO1992016562A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants
EP19920906335 EP0575407A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants
CA 2105980 CA2105980A1 (en) 1991-03-12 1992-03-12 Humanised antibodies having modified allotypic determinants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919105245A GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules

Publications (1)

Publication Number Publication Date
GB9105245D0 true GB9105245D0 (en) 1991-04-24

Family

ID=10691455

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919105245A Pending GB9105245D0 (en) 1991-03-12 1991-03-12 Binding molecules

Country Status (5)

Country Link
EP (1) EP0575407A1 (en)
JP (1) JPH06510659A (en)
CA (1) CA2105980A1 (en)
GB (1) GB9105245D0 (en)
WO (1) WO1992016562A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
ATE319745T1 (en) 1997-05-21 2006-03-15 Biovation Ltd METHOD FOR PRODUCING NON-IMMUNOGENIC PROTEINS
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (en) 1999-08-09 2009-05-29 Merck Patent Gmbh Multiple cytokine−antibody complexes
GB9925490D0 (en) * 1999-10-28 1999-12-29 Univ Cambridge Tech Binding molecules and treatment and screening methods
JP2003514552A (en) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
ES2288967T3 (en) 2000-06-29 2008-02-01 Merck Patent Gmbh REINFORCEMENT OF IMMUNE ANSWERS MEDIATED BY THE ANTIBODY-CYTOKIN FUSION PROTEIN THROUGH THE TREATMENT COMBINED BY AGENTS THAT IMPROVE THE INCORPORATION OF IMMUNOCITOQUINE.
BR0207854A (en) 2001-03-07 2004-08-24 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
HUP0400284A3 (en) 2001-05-03 2012-09-28 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
PL206975B1 (en) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokines with modulated selectivity
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
RU2366664C2 (en) 2002-12-17 2009-09-10 Мерк Патент Гмбх Humanised antibody (h14,18) based on mouse antibody 14,18, contacting gd2, and its fusion with il-2
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
BRPI0418286A (en) 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
BRPI0506771A (en) * 2004-01-12 2007-05-22 Applied Molecular Evolution antibody and pharmaceutical composition
PL1706428T3 (en) 2004-01-22 2010-02-26 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
MXPA06012601A (en) 2004-05-10 2007-05-10 Macrogenics Inc HUMANIZED FcgammaRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF.
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
JP5055603B2 (en) 2004-08-04 2012-10-24 メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー Mutated Fc region
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
RU2437893C2 (en) 2004-12-09 2011-12-27 Мерк Патент Гмбх Il-7 versions with low immunising capacity
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
AU2006332138B2 (en) 2005-12-30 2012-03-22 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
JP2009521912A (en) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CD19 antibody with reduced immunogenicity
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
HRP20140331T1 (en) 2006-08-14 2014-05-09 Xencor, Inc. OPTIMIZED CD19 DIRECTED ANTIBODIES
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
PL2235059T3 (en) 2007-12-26 2015-08-31 Xencor Inc Fc variants with altered binding to fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
CN106349390B (en) 2008-04-02 2019-12-10 宏观基因有限公司 BCR-complex-specific antibodies and methods of use thereof
EA201171259A1 (en) 2009-04-22 2012-05-30 Мерк Патент Гмбх ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120093229A (en) * 2009-09-24 2012-08-22 엑스바이오테크, 인크. Methods, compositions, and kits for reducing anti-antibody responses
PL2486141T3 (en) 2009-10-07 2018-07-31 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ES2667100T3 (en) 2010-08-02 2018-05-09 Macrogenics, Inc. Covalent Diabodies and Their Uses
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
SMT202100621T1 (en) 2012-07-13 2022-01-10 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG10201705245TA (en) 2013-03-14 2017-07-28 Macrogenics Inc Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN107108721B (en) 2014-09-29 2021-09-07 杜克大学 Bispecific molecules comprising HIV-1 envelope targeting arms
CR20180484A (en) 2016-04-15 2019-03-05 Macrogenics Inc NEW B7-H3 UNON MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059719T3 (en) * 1988-02-12 1994-11-16 British Tech Group IMPROVEMENTS RELATED TO ANTIBODIES.

Also Published As

Publication number Publication date
WO1992016562A1 (en) 1992-10-01
CA2105980A1 (en) 1992-09-13
EP0575407A1 (en) 1993-12-29
JPH06510659A (en) 1994-12-01

Similar Documents

Publication Publication Date Title
GB9105245D0 (en) Binding molecules
GB9316989D0 (en) Binding molecules
GB9225453D0 (en) Binding proteins
GB9016299D0 (en) Binding substances
AU671148C (en) Binding element
ZA937445B (en) Binding element
GB9209562D0 (en) Binding machines
GB9027767D0 (en) Binding substances
GB9210608D0 (en) Binding system
GB9105074D0 (en) Improvements in binding
GB9421412D0 (en) Binding
GB2274429B (en) Book binding
GB9125582D0 (en) Binding molecules 2
GB9125579D0 (en) Binding molecules 1
GB2281248B (en) Indicating binding times
GB2249524B (en) Book binding
GB9110549D0 (en) Binding substances
GB9104744D0 (en) Binding substances
GB9210120D0 (en) Binding molecules
GB9024503D0 (en) Binding substances
GB9212045D0 (en) Binding
GB9107227D0 (en) Clips
GB9120377D0 (en) Improved binding substances
GB9206372D0 (en) Binding substances
GB9122293D0 (en) Book